Genetic Technologies (ASX:GTG)

Genetic Technologies (ASX:GTG) Limited offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product,BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.

Latest Article

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.

READ ARTICLE

Top Trending